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Hypercalcitoninemia has frequently been reported as a marker for medullary thyroid carcinoma. Currently, calcitonin measurements 
are mostly useful in the evaluation of tumor size and progression, and as an index of biochemical improvement of medullary thyroid 
carcinomas. Although measurement of calcitonin is a highly sensitive method for the detection of medullary thyroid carcinoma, 
it presents a low specificity for this tumor. Several physiologic and pathologic conditions other than medullary thyroid carcinoma 
have been associated with increased levels of calcitonin. Several cases of thyroid nodules associated with increased values of 
calcitonin are not medullary thyroid carcinomas, but rather are related to other conditions, such as hypercalcemias, hypergastrin-
emias, neuroendocrine tumors, renal insufficiency, papillary and follicular thyroid carcinomas, and goiter. Furthermore, prolonged 
treatment with omeprazole (> 2-4 months), beta-blockers, glucocorticoids and potential secretagogues, have been associated with 
hypercalcitoninemia. An association between calcitonin levels and chronic auto-immune thyroiditis remains controversial. Patients 
with calcitonin levels >100 pg/mL have a high risk for medullary thyroid carcinoma (~90%-100%), whereas patients with values 
from 10 to 100 pg/mL (normal values: <8.5 pg/mL for men, < 5.0 pg/mL for women; immunochemiluminometric assay) have a 
<25% risk for medullary thyroid carcinoma. 
In multiple endocrine neoplasia type 2 (MEN2), RET mutation analysis is the gold-standard for the recommendation of total preven-
tive thyroidectomy to relatives at risk of harboring a germline RET mutation (50%). False-positive calcitonin results within MEN2 
families have led to incorrect indications of preventive total thyroidectomy to RET mutation negative relatives.
In this review, we focus on the differential diagnosis of hypercalcitoninemia, underlining its importance for the avoidance of mis-
diagnosis of medullary thyroid carcinoma and consequent incorrect recommendation for thyroid surgery. 
KEYWORDS: Calcitonin; False-positive test; RET mutation; Total thyroidectomy. 
INTRODUCTION
Calcitonin is a polypeptide hormone composed of 32 
amino acids that is secreted by thyroid C-cells.1 Serum 
calcitonin has been considered an excellent marker for 
medullary thyroid carcinoma (MTC).2 Until 1993, serum 
calcitonin measurement was the only reliable tool for the 
diagnosis of MTC.2-6 However, further studies documented 
that calcitonin, as a tumor marker for MTC, presented false-
positive and false-negative results.4 
There have also been reports of non-MTC patients who 
were erroneously submitted to total thyroidectomy due to 
recommendations based on elevated calcitonin values.7,8 
It has been shown that only 10% to 40% of all patients 
with high levels of calcitonin associated with a thyroid 
nodule actually have MTC.9 Based on these observations, 
this review aims to emphasize physiologic and pathologic 
conditions other than MTC that may be associated with high 
serum levels of calcitonin. 
Calcitonin measurements
Serum calcitonin values may be measured with several 
different assays. Radioimmunoassay (RIA) has been widely 
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used, but this assay may measure calcitonin-like proteins, 
in addition to calcitonin.1,5,10 The first-generation method 
used in our hospital was an RIA (DPC, Los Angeles, CA) 
that used polyclonal antibodies to detect calcitonin; it had 
an upper normal value of 50 pg/ml. The most common 
second-generation method is the immunoradiometry assay 
(IRMA), which uses two different antibodies to calcitonin 
(double-antibody method). It is more sensitive than the 
first-generation RIA and measures only the intact calcitonin 
molecule.1,11,12 The upper normal calcitonin value obtained 
by this method is 10 pg/ml.11 A third-generation method for 
calcitonin detection, the immunochemiluminescent assay 
(ICMA), is now routinely used in our tertiary academic 
hospital. Normal basal calcitonin values detected by ICMA 
are lower than 5.0 pg/ml for women and lower than 8.5 
pg/ml for men (DPC, Los Angeles, CA). These two latter 
methods (IRMA and ICMA) are highly reliable and sensitive 
assays that use two antibodies to detect the monomeric form 
of the calcitonin molecule. Consequently, they are currently 
the two most commonly used methods. 
Sensitivity and specificity 
An elevated level of serum calcitonin is a highly sensitive 
marker for MTC, but it is not especially specific.9,13,14-20 Only 
10% to 40% of all patients with thyroid nodules associated 
with high basal levels of calcitonin also had MTC.9 
Therefore, in the remaining 60% to 90% of patients, elevated 
calcitonin values are secondary to other conditions (Table 
1). Further, these results may also be due to problems in the 
methodology, the presence of endogenous anti-calcitonin 
antibodies, or even to chronic exposure to tobacco smoke. 
Also, serum calcitonin levels vary by sex, age, weight and 
physical activity.2,21-23
Differential diagnosis of hypercalcitoninemia
Before performing the diagnosis of MTC, the conditions 
shown in Table 1 and discussed below should be considered 
and discarded in cases with hypercalcitoninemia. As seen 
in Table 2, the differential diagnosis of MTC should be the 
made in cases with basal calcitonin values between 10 and 
100 pg/mL (determined by IRMA or ICMA). 
Hypergastrinemia: High levels of gastrin stimulate 
the synthesis and secretion of calcitonin, therefore raising 
its serum levels.2-4 Gastrin, in the form of pentagastrin, is 
largely used in stimulatory tests that evaluate the capacity 
of C-cells5 to secrete calcitonin. Conditions associated with 
hypergastrinemia, such as atrophic gastritis and gastrinoma, 
may present increased levels of calcitonin.16
Omeprazole: The chronic use of omeprazole or 
omeprazole-like drugs raises calcitonin serum levels after 
2 to 4 months of treatment.16,19 These drugs may lead to 
constant stimulation of gastric G-cells and induce gastrin 
hypersecretion, ultimately leading to high serum levels of 
calcitonin. Omeprazole’s action on calcitonin levels is well 
recognized. It has been proposed as a potential stimulatory 
test for calcitonin secretion.24
Hypercalcemia: Calcium is a strong calcitonin 
secretagogue that is currently used to evaluate calcitonin 
secretion. In this test, calcium is acutely injected (2 mg/
kg body weight) for 30 seconds and blood collection is 
performed at -5, 0, 2, 5, and 10 min from injection.2-5 Thus, 
conditions that cause persistently high levels of calcium, 
Table 1- Hypercalcitoninemia in non-medullary thyroid 
carcinoma conditions
Physiologic conditions2,35,36 Sex
Age
Physical activity
Drugs2, 29,32 Omeprazole and similar drugs (interfere 
with the H+ pump)
Glucocorticoids
Beta-blockers
Glucagon
CGRP
Enteroglucagon
Pancreozimine
Non-thyroid 
pathologies2-4,5,28,29,34
Hypergastrinemias
Hypercalcemias (hyperparathyroidism)
Renal insufficiency
Neuroendocrine tumors:
pheochromocytoma
paraganglioma
enteropancreatic endocrine tumors
VIPoma
insulinomacarcinoids
small cell pulmonary tumor
Thyroid 
pathologies2,9,20,36,38,39,40
Thyroid carcinomas: 
follicular carcinoma
papillary carcinoma
Chronic autoimmune thyroiditis*
* There is some debate on this subject (see text)
Table 2 - Calcitonin values and risk for medullary thyroid 
carcinoma*
Value (pg/ml) Risk for MTC
>100 Extremely high (100%)
≥ 50 and < 100** Moderate (25%)
≥ 20 and < 50** Low (8.3%)
<8.5 for men/<5.0 for women Normal
* Based on Constante et al., 2007. ** It is recommended to systematically 
investigate non-MTC conditions in patients with calcitonin levels in these 
ranges.
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such as hyperparathyroidism and others, may lead to higher 
levels of calcitonin. 
Renal insufficiency: The calcitonin clearance rate is 
lowered in patients with chronic renal insufficiency. This 
effect may lead to increased levels of calcitonin in the 
blood.17,18
Thyroid carcinomas: Follicular and papillary thyroid 
carcinomas have been reported to be associated with C-cell 
hyperplasia and high levels of calcitonin.2,9,10,25 It has been 
proposed that these tumors may release substances that 
possess a paracrine stimulatory action on the C-cells and will 
thus eventually raise serum calcitonin levels. 
Neuroendocr ine  tumors :  Severa l  types  o f 
neuroendocrine tumors can ectopically secrete calcitonin. 
Such tumors, including paragangliomas, might be associated 
with increased levels of calcitonin, even in cases where there 
is a negative immunohistochemistry reaction for calcitonin.26 
Hypercalcitoninemia has also been reported in patients with 
pheochromocytoma, enteropancreatic endocrine tumors, 
VIPomas, insulinomas, gastric carcinoids and small cells 
pulmonary tumors.15,16,22
Chronic autoimmune thyroiditis: As yet, no general 
consensus has been achieved regarding the levels of 
calcitonin in Hashimoto thyroiditis. Barbot et al. reported 
high calcitonin levels in 3/24 patients (12.5%) with 
Hashimoto thyroiditis.27 Others stated that up to 20% 
of patients with chronic lymphocytic thyroiditis present 
C-cell hyperplasia28 that may lead to increased calcitonin 
levels. We analyzed calcitonin responses during a calcium/
pentagastrin infusion test in 27 patients with chronic 
autoimmune thyroiditis (CAT) during either the goitrous 
(early) or agoitrous/atrophic (late) stages of this disease and 
in 30 healthy adult controls.11 Sixteen cases were diagnosed 
at the advanced, atrophic thyroid stage of CAT and eleven 
cases at the early, goitrous stage. We found significantly 
lowered basal and stimulated calcitonin values in patients at 
both stages of CAT. These findings were confirmed by other 
studies.12 The limited secretory reserve of calcitonin noted 
in these CAT cases may be a consequence of a progressive 
C-cell destruction following nonspecific follicular and para-
follicular cell damage caused by progressive lymphocytic 
infiltration and fibrosis of the thyroid gland.29 In another 
study, a significant decrease in C-cell number was observed 
in cases with CAT compared to normal thyroids. These data 
indicate that the inflammatory process caused destruction of 
both follicular and C cells, which were ultimately replaced 
by fibrosis.30
Other secretagogues: Many drugs have been reported 
to raise calcitonin serum levels, such as glucocorticoids, 
glucagon, CGRP, enteroglucagon, pancreozimine, and beta 
blockers.2
Physiologic conditions: Sex, age and physical activity 
may affect the synthesis and/or secretion of calcitonin.2,24,25 
More specifically, physical activity can induce small 
elevations in the calcitonin level; women present lower 
basal calcitonin levels (<5 pg/ml) compared to men (<8.5 
pg/ml); and the elderly present lower levels than younger 
individuals. 
False positive results and erroneous indication of total 
thyroidectomy
Considering the above information, it is not surprising 
that false-positive calcitonin results have led to erroneous 
recommendations of total thyroidectomy.7,8,25,31,32
Høie and colleagues8 reported a multiple endocrine 
neoplasia type 2 (MEN2A) family in which two relatives 
were recommended for preventive total thyroidectomy based 
on their high levels of calcitonin; one of the relatives was a 
6-year-old child. Later, both cases were confirmed as having 
no germline RET mutation. Marsh and colleagues7 similarly 
reported two patients belonging to a MEN2A family 
who underwent total thyroidectomy based solely on their 
calcitonin levels. Soon after, both individuals were confirmed 
as being negative for the RET mutation. Therefore, the 
recommendation and surgical option of total thyroidectomy 
were inappropriate for both families.
Similarly, Papapetrou and colleagues21 reported a patient 
who underwent total thyroidectomy due to the detection of 
high levels of calcitonin that were, in fact, caused by anti-
calcitonin antibodies. In 2007, Galitz and colleagues25 showed 
that four patients with thyroid nodules and high serum levels 
of calcitonin were recommended for total thyroidectomy. 
However, the pathologic findings revealed either lymphocytic 
thyroiditis or papillary thyroid carcinoma in these cases. 
We followed up two young girls belonging to a 
MEN2 family who were recommended for preventive 
total thyroidectomy in another hospital based on slightly 
increased basal calcitonin levels. Soon after, RET mutation 
analysis performed in our laboratory revealed that neither at-
risk girl harbored any RET mutation in the six examined hot-
spot exons. The germline RET Cys620Arg mutation found in 
other at risk members of this family were not present in these 
two young girls (manuscript in preparation). 
Therefore, in order to avoid misdiagnosis and unnecessary 
thyroid surgeries, it is imperative to conduct a thorough 
investigation in cases with elevated basal levels of calcitonin 
to exclude possible diagnoses other than MTC (Table 1).
An approach for individuals at-risk for MTC 
The National Institute of Health (NIH) guidelines for 
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MEN patients recommends that all cases of MTC, either 
sporadic or inherited, should be analyzed for mutations in 
the RET proto-oncogene.4 As has been stated, RET molecular 
diagnosis is considered the gold-standard for the recognition 
of patients at-risk for MTC in MEN2 families.4 For the 
great majority of asymptomatic carriers of RET proto-
oncogene mutations, a prophylactic total thyroidectomy is 
recommended before 5 years of age.4 
Calcitonin measurements in thyroid nodules
The routine measurement of calcitonin to screen for 
MTC in patients with nodular thyroid disease is still 
controversial. Several researchers recommend it, 9,32-35 
including the European consensus group.36 However, the 
American Thyroid Association37 has raised concerns about 
some possible limitations to this procedure. Although only 
10% to 40% of patients with thyroid nodules and high 
levels calcitonin may harbor an MTC, routine calcitonin 
measurement in these cases (mostly in those with solid 
nodules) has been demonstrated to be beneficial.9
Frequently, patients with MTC (mostly those with the 
sporadic form) are diagnosed at a later stage of the disease. 
Many of these cases will be recognized only after the 
detection of a single palpable thyroid nodule (larger than 
1cm in diameter), hypercalcitoninemia and cytologic and 
pathologic findings compatible with MTC. Whenever a 
patient presents a palpable nodule, the MTC tumor will have 
evolved for nearly 4 years and have a 50% to 70% risk for 
cervical lymph node metastases.2-4 
Constante et al.33 measured serum calcitonin values in 
5,815 patients with thyroid nodules. Of these patients, 15 
were diagnosed with MTC and 7 with C-cell hyperplasia. 
They reported that stimulated calcitonin values of above 100 
pg/ml, after pentagastrin infusion, predicted MTC in 40% 
of cases. In the experience of the authors, basal calcitonin 
values higher than 100 pg/ml are 100% predictive of MTC; 
values between 50 and 100 pg/ml are 25% predictive 
of MTC, and values from 20 to 50 pg/ml are only 8.3% 
predictive of MTC (Table 2). 
Scheuba et al.38 studied basal and stimulated 
calcitonin values in 260 patients with thyroid nodules and 
hypercalcitoninemia. They concluded that all patients 
with basal calcitonin levels above 64 pg/ml and stimulated 
calcitonin values above 560 pg/ml presented MTC. They 
also reported that MTC was documented in 20% of patients 
with basal calcitonin values ranging from 10 pg/ml to 64 pg/
ml and calcitonin-stimulated levels ranging from 100 pg/ml 
to 560 pg/ml.
Borget et al.9 estimated that of about 74,000 patients with 
thyroid nodules in France, 3,600 of them have elevated levels 
of calcitonin and, among those, approximately 300 have an 
MTC. In Brazil, we estimate that there are nearly 220,000 
cases with thyroid nodules and that 5% of them might 
present high levels of calcitonin. Within the estimated 11,000 
patients with hypercalcitoninemia, 10% to 40% (1,100 to 
4,400) might harbor MTC. 
Cheung et al.39 performed a study to determine the 
cost-effectiveness (C/E) of routine calcitonin screening 
in adult patients with thyroid nodules in the United States 
of America (USA). They concluded that routine serum 
calcitonin screening in patients undergoing evaluation for 
thyroid nodules appears to be cost-effective in USA, with 
C/E comparable to the measurement of thyroid stimulating 
hormone, colonoscopy, and mammography screenings.
Multiple endocrine neoplasias
Multiple endocrine neoplasias (MENs) were recently 
pointed to as a representation of the syndromes of the 20th 
century, as they were first described in the early 1900s and 
their clinical, biochemical and molecular features were fully 
defined by 2000.40 
MEN type 1 (MEN1) encompasses a series of up to 20 
endocrine and non-endocrine tumors caused by a mutation 
in the tumor suppression gene MEN1.2-4 The impact of the 
description of MEN1 mutations in the clinical approach 
taken with MEN1 patients has been evaluated in several 
studies.4,41-43 Recent data indicate that other genes, such 
as p27Kip1, may be involved in cases with MEN1-like 
phenotypes.44,45 
Multiple endocrine neoplasia type 2 (MEN2) is 
characterized by the occurrence of MTC, primary 
hyperparathyroidism (HPT) and pheochromocytoma. It is 
caused by germline mutations in the RET proto-oncogene.2-4
MTC represents approximately 5% of all thyroid 
carcinomas, and from 0.5% to 1% of all thyroid nodules.2,3,9 
Up to 70% of patients with MTC present with the sporadic 
form of the disease (s-MTC), frequently related to somatic 
mutations; the other 30% of cases present with the inherited 
forms of MTC caused by germline mutations in the RET 
proto-oncogene4. These two forms of MTC are markedly 
distinct and should be recognized as such to allow for 
adequate management.2-4
Sporadic medullary thyroid carcinoma (s-MTC)
s-MTC typically occurs at a later age than the inherited 
forms of MTC. It is characterized by the presence of a 
single, unilateral thyroid nodule and the absence of other 
tumors associated with MTC, such as pheochromocytoma 
and HPT. There are no similar cases in the family of 
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the affected individuals. Measurements of calcitonin in 
these cases remain a powerful tool for diagnosis,3 and 
thus abnormally high levels of calcitonin (>100 pg/ml) in 
patients with or without a thyroid nodule may be indicative 
of MTC.2-4,46 These patients do not have a germline mutation 
in the RET proto-oncogene, but 20%-40% may present 
with a somatic mutation of the RET proto-oncogene, most 
commonly at codon 918 (M918T c.2753T>C), in the 
thyroid tumor tissue. It is reported that up to 5% of apparent 
s-MTC cases may harbor an unsuspected germline RET 
mutation.2-4,46 
Inherited medullary thyroid carcinoma
Inherited MTC occurs at earlier ages than s-MTC and 
always presents at a pre-malignant C-cell hyperplasia stage. 
It is usually bilateral and caused by activating mutations in 
the RET gene, which encodes the RET receptor2-.4,10,13,28,47,48 
MTC occurs as the predominant component of MEN2 
syndromes:2,3 a) familial MTC (F-MTC), in which MTC 
is the only MEN2-related tumor occurring in at least 10 
members of a same family, b) MEN2A, in which MTC is 
associated with HPT and pheochromocytoma, c) MEN2B, 
in which MTC is associated with HPT, pheochromocytoma, 
skeletal abnormalities, and multiple neuromas of the lips, 
tongue, and gastrointestinal tract.2
The analysis of germline mutations in the RET proto-
oncogene is considered the gold-standard for the study of 
MEN2 families.4,13,49 Presently, measurements of calcitonin 
in patients with inherited MTC are restricted to studies 
of tumor progression and post-surgical outcomes.4,50 As 
discussed above, pre-surgical calcitonin values in this 
condition should be carefully interpreted, considering the 
several reports of false-positive and false-negative results of 
calcitonin as a marker for MTC.4,7,8,21,31,50,51
C-cell hyperplasia
C-cell hyperplasia (CCH) is indicated by the presence, 
in a thyroid cross section, of more than 50 C-cells in at least 
three microscope fields (100X magnification) and at least 
40 C-cells by cm2. CCH is intrinsically related to MTC 
associated with MEN2 (primary C-cell hyperplasia), but may 
also occur in a series of other non-inherited endocrine and 
non-endocrine disorders (secondary C-cell hyperplasia).2-4,10 
Surprisingly, up to 20% of normal individuals may present 
with this condition.14
Thus, CCH is not pathognomonic of MTC associated 
with MEN2. CCH is usually related to augmented calcitonin 
synthesis and secretion, and therefore high serum levels of 
this hormone. In the set of inherited forms of MTC, CCH 
constitutes a progressive and pre-malignant stage. In most 
MEN2 patients, CCH will evolve to micro-focal MTC and 
eventually to larger tumors.2 Frequently, MTCs in MEN2 are 
surrounded by extensive areas of CCH.10
Consensus on MENs recommendations
It is important to follow the recommendations of the 
NIH Consensus on MENs.4 Preventive total thyroidectomy 
should only be recommended to MTC/MEN2 patients’ 
relatives based on the results of RET mutation analysis, not 
on calcitonin levels alone. The Consensus also recommends 
the performance of RET proto-oncogene mutation analysis 
in all patients with s-MTC, since 5% of them may have 
unsuspected RET germline mutations. Hence, calcitonin 
measurement for screening of at-risk relatives in MEN2 
families has been definitively replaced by RET proto-
oncogene mutation analysis, due to the false-positive and 
false-negative calcitonin results and the high accuracy of 
RET analysis.
Hospital das Clínicas of the University of São Paulo 
School of Medicine (HC-FMUSP) experience
We began s tudying MTC/MEN2 in  the  pre-
genomic phase, when calcitonin measurements and 
immunohistochemistry analysis were the best available 
diagnostic tools.1,5,10 In the post-genomic phase, we have 
used automated sequencing mutation analysis of the RET 
proto-oncogene.47,48 In the RET study, we have shown the 
efficiency of screening methods such as SSCP, DGGE 
and CSGE.28,47,48,52 Abelin et al.34 conducted the first 
measurements of calcitonin in a limited set of patients 
presenting with a single, solid thyroid nodule and advocate 
calcitonin measurement as a routine procedure. These 
authors reported MTC in ~1% of examined cases. We have 
documented calcitonin deficiency in patients with chronic 
autoimmune thyroiditis, either in the goitrous or atrophic 
phase.11 Furthermore, the Head and Neck Surgery Group 
of our institution has established a careful routine surgical 
procedure for all RET-positive carriers.53
CONCLUSIONS
Some conclusions may be stated from this review. We 
conclude that: 
a) all patients with increased levels of serum calcitonin 
(with or without thyroid nodule) should be submitted to 
a careful and thorough investigation in order to rule out 
conditions other than MTC; 
b)  preventive total  thyroidectomy should be 
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recommended and performed in all at-risk relatives of 
MEN2 patients based on RET mutation analysis, not solely 
on serum calcitonin levels; 
c) although only 10% to 40% of unselected cases with 
hypercalcitoninemia and thyroid nodule will have MTC, 
routine calcitonin measurements are recommended in these 
patients in order to reach an earlier MTC diagnosis. 
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